Home › NCT06087029

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Who can join

Ages 21 and older · All sexes

Inclusion Criteria:

1. Age \> 21 years
2. Patients with a Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion syndrome (renal, mesenteric, or extremity) who are within 48 hours to 6 weeks after start of index admission for their type B dissection
3. Ability to provide written informed consent
4. Investigator believes anatomy is suitable for TEVAR

Exclusion Criteria:

1. Ongoing systemic infection
2. Pregnant or planning to become pregnant in the next 3 months
3. Life expectancy related to non-aortic conditions \< 2 years
4. Unwilling or unable to comply with all study procedures
5. Known patient history of genetic aortopathy
6. Penetrating Aortic Ulcer without concomitant uTBAD
7. Intramural hematoma without concomitant uTBAD
8. Iatrogenic (traumatic) aortic dissection

About the study

The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

What is being tested

• TEVAR (procedure)
• Guideline directed medical therapy and surveillance of dissection (other)

Sponsor: Duke University · Participants: 1,100 · Started: Apr 14, 2024

Contact the study team

• Megan Roebuck, M.S. · Phone: 919-316-0628
• Kady-Ann Steen-Burrell, Ph.D. · Phone: 919-530-9711

Official record on ClinicalTrials.gov — NCT06087029

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.